Oncology drugs such as Keytruda and Opdivo represent what could be considered a revolution in cancer biology research into new therapeutics. This is because these drugs target the immune system of the tumor microenvironment--which can either be facilitating tumor growth or effectively combating it--rather than the tumor tissue itself. As PLMI President Dr. Jeffrey Bland explains in this new video, this research represents an obvious connection to personalized lifestyle medicine because the immune system being influenced by drugs like Keytruda and Opdivo is also being influenced by the environment of the host (that is, the communication system between the immune system and the patient's environment). Factors influencing this system include such things as insulin signaling, redox potential, oxygen tension within cells, and mitochondrial oxidative function.
Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015 Oct 6;34:111.
Block KI, Gyllenhaal C, Lowe L, Amedei A, Ruhul Amin ARM, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015 Dec;35 Suppl:S276-304.
Pistollato F, Giampieri F, Battino M. The use of plant-derived bioactive compounds to target cancer stem cells and modulate tumor microenvironment. Food Chem Toxicol. 2015 Jan;75:58-70